CL2016003273A1 - Composiciones antimicrobianas con agentes efervescentes - Google Patents

Composiciones antimicrobianas con agentes efervescentes

Info

Publication number
CL2016003273A1
CL2016003273A1 CL2016003273A CL2016003273A CL2016003273A1 CL 2016003273 A1 CL2016003273 A1 CL 2016003273A1 CL 2016003273 A CL2016003273 A CL 2016003273A CL 2016003273 A CL2016003273 A CL 2016003273A CL 2016003273 A1 CL2016003273 A1 CL 2016003273A1
Authority
CL
Chile
Prior art keywords
compositions
antimicrobial compositions
effervescent agents
gastrointestinal
quinolona
Prior art date
Application number
CL2016003273A
Other languages
English (en)
Inventor
Danping Li
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54868661&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016003273(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of CL2016003273A1 publication Critical patent/CL2016003273A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE RELACIONA CON COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN UN AGENTE ANTIMICROBIANO DERIVADO DE ÁCIDO QUINOLONA CARBOXÍLICO Y UN AGENTE EFERVESCENTE. ESTAS COMPOSICIONES TIENEN TOLERABILIDAD GASTROINTESTINAL MEJORADA Y/O MENOS PROBABILIDADES DE CAUSAR EFECTOS SECUNDARIOS GASTROINTESTINALES. ESTAS COMPOSICIONES SON ÚTILES PARA LA ADMINISTRACIÓN ORAL, PARA TRATAR, PREVENIR, O REDUCIR EL RIESGO DE INFECCIONES MICROBIANAS.</p>
CL2016003273A 2014-06-20 2016-12-20 Composiciones antimicrobianas con agentes efervescentes CL2016003273A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462014786P 2014-06-20 2014-06-20

Publications (1)

Publication Number Publication Date
CL2016003273A1 true CL2016003273A1 (es) 2017-08-04

Family

ID=54868661

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2016003273A CL2016003273A1 (es) 2014-06-20 2016-12-20 Composiciones antimicrobianas con agentes efervescentes
CL2020003153A CL2020003153A1 (es) 2014-06-20 2020-12-03 Composiciones antimicrobianas con agentes efervescentes (divisional de solicitud n° 03273-2016)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2020003153A CL2020003153A1 (es) 2014-06-20 2020-12-03 Composiciones antimicrobianas con agentes efervescentes (divisional de solicitud n° 03273-2016)

Country Status (32)

Country Link
US (2) US20150366857A1 (es)
EP (3) EP3581180B1 (es)
JP (2) JP6995479B2 (es)
CN (2) CN106572982B9 (es)
AR (1) AR100920A1 (es)
AU (3) AU2015276954B2 (es)
BR (1) BR112016029761B1 (es)
CA (1) CA2952950C (es)
CL (2) CL2016003273A1 (es)
CR (2) CR20160592A (es)
CY (2) CY1121995T1 (es)
DK (2) DK3157510T3 (es)
EA (1) EA034152B1 (es)
EC (1) ECSP16095540A (es)
ES (2) ES2732865T3 (es)
HR (2) HRP20211685T1 (es)
HU (2) HUE056298T2 (es)
IL (1) IL249622A0 (es)
LT (2) LT3581180T (es)
MX (2) MX368940B (es)
PE (2) PE20170304A1 (es)
PH (2) PH12022550979A1 (es)
PL (2) PL3157510T3 (es)
PT (2) PT3581180T (es)
RS (2) RS62538B1 (es)
SI (2) SI3581180T1 (es)
SM (2) SMT201900348T1 (es)
SV (1) SV2016005349A (es)
TR (1) TR201909417T4 (es)
TW (2) TWI732337B (es)
UY (1) UY36184A (es)
WO (1) WO2015196027A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022240897A1 (en) * 2021-05-10 2022-11-17 Sepelo Therapeutics, Llc Pharmaceutical composition comprising delafloxacin for administration into the lung

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194617A (en) * 1988-12-17 1993-03-16 Meiji Seika Kaisha, Ltd. 2,3-disubstituted-4-hydroxyquinoline derivatives
US5223264A (en) * 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
ES2200439T3 (es) 1995-09-22 2004-03-01 Wakunaga Pharmaceutical Co., Ltd. Intermedios para utilizar en la preparacion de nuevos derivados del acido piridonocarboxilico o sus sales.
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
DE19814256A1 (de) * 1998-03-31 1999-10-07 Asta Medica Ag Feste, schnellzerfallende Cetirizin-Formulierungen
AP1659A (en) * 1998-09-14 2006-09-06 Ranbaxy Laboratories Ltd Orally administered controlled drug delivery system providing temporal and spatial control.
US6187317B1 (en) * 1999-07-14 2001-02-13 Judith Taylor Natural anti-diarrheal composition and method
US6414036B1 (en) * 1999-09-01 2002-07-02 Van Beek Global/Ninkov Llc Composition for treatment of infections of humans and animals
JP2005097116A (ja) 1999-11-11 2005-04-14 Wakunaga Pharmaceut Co Ltd キノリンカルボン酸誘導体アルカリ金属塩及びこれを用いたキノリンカルボン酸誘導体の精製法
US7157100B2 (en) * 2002-06-04 2007-01-02 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
EP1789392A2 (en) 2004-07-30 2007-05-30 Abbott Laboratories Preparation of pyridonecarboxylic acid antibacterials
US7728143B2 (en) 2004-10-08 2010-06-01 Abbott Laboratories Salt and crystalline forms thereof of a drug
PL2486942T3 (pl) * 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Kompozycje zawierające azelastynę oraz sposoby ich stosowania
SI1868581T1 (sl) 2005-04-11 2012-06-29 Abbott Lab Farmacevtski sestavki z izboljšanim profilom topnosti za slabo topna zdravila
ATE396710T1 (de) * 2005-07-19 2008-06-15 Ethypharm Sa Gastroretentive zusammensetzungen und verfahren zur herstellung
US7611739B2 (en) * 2006-01-06 2009-11-03 Amerilab Technologies, Inc. Method of using guava extract and composition including guava extract
US7892447B2 (en) * 2006-08-11 2011-02-22 Aqua Resources Corporation Nanoplatelet metal hydroxides and methods of preparing same
CN1943561A (zh) * 2006-08-23 2007-04-11 北京阜康仁生物制药科技有限公司 普卢利沙星口腔崩解片及其制备方法
WO2008080092A2 (en) * 2006-12-22 2008-07-03 Ironwood Pharmaceuticals, Inc. Compositions comprising bile acid sequestrants for treating esophageal disorders
US8821928B2 (en) * 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
BR122020021551B1 (pt) * 2008-11-15 2021-09-21 Melinta Subsidiary Corp Composição farmacêutica antimicrobiana e seu uso
WO2010096551A2 (en) * 2009-02-18 2010-08-26 Rib-X Pharmaceuticals, Inc. Antimicrobial compositions
GB201020076D0 (en) * 2010-11-26 2011-01-12 Liverpool School Tropical Medicine Antimalarial compounds
EP3238722B1 (en) * 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones
MX341342B (es) * 2011-01-14 2016-08-17 Vertex Pharma Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2 -(1-hidroxi-1-metil-etil) pirimidin-5-il]-7-(tetrahidrofuran-2-il) -1h-benzimidazol-2-il]urea.
JP2013034468A (ja) * 2011-08-10 2013-02-21 Nisshin Sugar Mfg Co Ltd 発泡成型甘味料
WO2013090893A1 (en) * 2011-12-16 2013-06-20 Celanese Eva Performance Polymers, Inc. Gastroretentive controlled release vehicles that include ethylene copolymers, ethyl celluloses, and/or thermpoplastic polyurethanes
CN102697751A (zh) * 2012-05-30 2012-10-03 河南牧翔动物药业有限公司 一种畜禽专用恩诺沙星泡腾分散片及其制备方法

Also Published As

Publication number Publication date
TW201625249A (zh) 2016-07-16
SMT201900348T1 (it) 2019-09-09
MX368940B (es) 2019-10-21
TWI705814B (zh) 2020-10-01
MX386171B (es) 2025-03-18
IL249622A0 (en) 2017-02-28
WO2015196027A1 (en) 2015-12-23
AU2021286284A1 (en) 2022-01-06
SI3157510T1 (sl) 2019-09-30
CR20160592A (es) 2017-02-21
LT3581180T (lt) 2021-12-27
TW202005650A (zh) 2020-02-01
CL2020003153A1 (es) 2021-06-25
MX2019012608A (es) 2019-12-02
SV2016005349A (es) 2017-08-31
JP2020183415A (ja) 2020-11-12
PL3581180T3 (pl) 2022-02-07
AU2015276954B2 (en) 2020-07-23
CN106572982A (zh) 2017-04-19
RS59064B1 (sr) 2019-08-30
DK3157510T3 (da) 2019-07-01
CN106572982B (zh) 2022-06-03
CN114831955B (zh) 2024-03-12
MX2016017350A (es) 2017-04-06
PH12016502548B1 (en) 2023-05-24
SMT202100618T1 (it) 2022-01-10
BR112016029761A2 (pt) 2017-08-22
JP7149991B2 (ja) 2022-10-07
ECSP16095540A (es) 2017-03-31
HUE044764T2 (hu) 2019-11-28
ES2897576T3 (es) 2022-03-01
CA2952950C (en) 2023-11-14
US20150366857A1 (en) 2015-12-24
PE20170304A1 (es) 2017-04-19
CN106572982B9 (zh) 2022-07-08
TR201909417T4 (tr) 2019-07-22
EP3919057B1 (en) 2026-01-28
HUE056298T2 (hu) 2022-02-28
CY1121995T1 (el) 2020-10-14
CA2952950A1 (en) 2015-12-23
PL3157510T3 (pl) 2019-12-31
PH12016502548A1 (en) 2017-04-10
AU2015276954A1 (en) 2017-01-12
PT3157510T (pt) 2019-06-21
JP2017518349A (ja) 2017-07-06
CY1125395T1 (el) 2023-03-24
EA034152B1 (ru) 2020-01-09
NZ727638A (en) 2023-08-25
PT3581180T (pt) 2021-11-09
EP3157510A1 (en) 2017-04-26
PH12022550979A1 (en) 2023-06-26
CN114831955A (zh) 2022-08-02
US20200237744A1 (en) 2020-07-30
EP3919057A1 (en) 2021-12-08
BR112016029761B1 (pt) 2023-03-07
TWI732337B (zh) 2021-07-01
JP6995479B2 (ja) 2022-01-14
EA201692532A1 (ru) 2017-05-31
AU2020256457A1 (en) 2020-11-12
HRP20191133T1 (hr) 2019-09-20
AU2021286284B2 (en) 2024-02-29
CR20200565A (es) 2021-01-14
HRP20211685T1 (hr) 2022-02-04
EP3581180B1 (en) 2021-08-04
AR100920A1 (es) 2016-11-09
DK3581180T3 (da) 2021-11-08
EP3581180A1 (en) 2019-12-18
EP3157510B1 (en) 2019-03-27
UY36184A (es) 2016-01-29
RS62538B1 (sr) 2021-12-31
BR112016029761A8 (pt) 2021-06-29
PE20210927A1 (es) 2021-05-19
AU2020256457B2 (en) 2021-09-30
SI3581180T1 (sl) 2021-12-31
EP3157510A4 (en) 2018-02-21
ES2732865T3 (es) 2019-11-26
LT3157510T (lt) 2019-09-25

Similar Documents

Publication Publication Date Title
CY1124013T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1123381T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
CY1125136T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CL2018001349A1 (es) Composiciones que comprenden cepas bacterianas
CL2018001367A1 (es) Composiciones que comprenden cepas bacterianas
MX354123B (es) Composición antiséptica oral para tratamiento de mucositis oral.
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
MX381776B (es) Formulacion acuosa que comprende paracetamol e ibuprofeno.
PE20150199A1 (es) Composiciones farmaceuticas y tratamiento de mastitis
CL2017000178A1 (es) Compuestos para usar en el tratamiento antihelmíntico
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CL2017002803A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
CL2020003153A1 (es) Composiciones antimicrobianas con agentes efervescentes (divisional de solicitud n° 03273-2016)
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
CL2016003271A1 (es) Métodos para tratar infecciones
BR112016024236A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
ZA201902956B (en) Antimicrobial formulations for the improved treatment of veterinary hoof infections
CR20160591A (es) Metodos para tratar infecciones
MX2019007390A (es) Peptidos antimicrobianos y usos de los mismos.
MX350565B (es) Composiciones farmaceuticas.
BR112017019413A2 (pt) combinação de agente bactericida com um agente alcalinizante lisossomotrópico para o tratamento de uma infecção bacteriana
UA101533U (uk) Полівалентний оральний гель для лікування і профілактики післяімплантаційних ускладнень